Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 152.16

+0.4%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (988)	10/9/2002 6:58:54 PM
From: Miljenko Zuanic	Read Replies (1) of 1834

Received respond from NBIX regards the article in JCI. ""We have no evidence of anaphylaxis in any of the preclinical studies, some out as long as one year, that we have done with the APL, including NOD mice. Moreover, in over 100 patients treated with the NBI-6024, we have no evidence of hypersensitivity and/or anaphylaxis. The diabetes community has safely administered the protein insulin for over twenty years subcutaneously, with little or no evidence for anaphylaxis."" Thanks, Paul and Conlon. I have no reason not to believe them. Also, as they mentioned, appropriate approach dealing with proteins and proteins fragments are warranted. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next